Clinical Trial Update: A Comparison of NETSPOT Imaging Versus F-FDG-PET in Head and Neck Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 trial comparing NETSPOT imaging (gallium-68 DOTATATE) with standard F-FDG-PET for detecting head and neck squamous cell carcinoma; results have been pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• FDG (fluorodeoxyglucose)
• NETSPOT (gallium-68 DOTATATE)

Snippet

Sponsor: West Virginia University | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2025-03-12